Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF
Study sponsor: Vicore Pharma AB
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-03-30Actual
Enrollment · participants52Actual
Source updated2025-05-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.